Biosimilars

Guidelines for Biosimilar Use for Treatment of Rheumatologic Diseases

Guidelines for Biosimilar Use for Treatment of Rheumatologic Diseases

By

Consensus recommendations on the use of biosimilars for the treatment of patients with rheumatologic diseases were recently published in Annals of the Rheumatic Diseases.

Interchangeability Study Initiated for Adalimumab Biosimilar

Interchangeability Study Initiated for Adalimumab Biosimilar

By

Boehringer Ingelheim has initiated a clinical study to investigate the interchangeability between an adalimumab biosimilar candidate and Humira.

FDA Recommendations For Naming of Biologics

FDA Recommendations For Naming of Biologics

The FDA has issued a final guidance document for the naming of reference biological products and biosimilars.

Sign Up for Free e-Newsletters